PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
25986565-10	2015	The proline-rich loop overhanging the FKBP52 FK1 catalytic domain is functionally important and likely represents an interaction surface within the receptor-chaperone complex.	Proline	4-11	FK506 binding protein 4	Mus musculus	38-44
25986565-6	2015	Additionally, the fkbp52-deficient mice display specific phenotypes related to androgen, progesterone, and glucocorticoid insensitivity suggesting minimal off-target effects.	Progesterone	89-101	FK506 binding protein 4	Mus musculus	18-24
25986565-7	2015	Finally, the fact that FKBP52 is already a validated target of the clinically approved immunosuppressive drug, FK506 (Tacrolimus), indicates that FKBP52 is a "druggable" protein.	Tacrolimus	111-116	FK506 binding protein 4	Mus musculus	23-29
25986565-7	2015	Finally, the fact that FKBP52 is already a validated target of the clinically approved immunosuppressive drug, FK506 (Tacrolimus), indicates that FKBP52 is a "druggable" protein.	Tacrolimus	111-116	FK506 binding protein 4	Mus musculus	146-152
25986565-7	2015	Finally, the fact that FKBP52 is already a validated target of the clinically approved immunosuppressive drug, FK506 (Tacrolimus), indicates that FKBP52 is a "druggable" protein.	Tacrolimus	118-128	FK506 binding protein 4	Mus musculus	23-29
25986565-7	2015	Finally, the fact that FKBP52 is already a validated target of the clinically approved immunosuppressive drug, FK506 (Tacrolimus), indicates that FKBP52 is a "druggable" protein.	Tacrolimus	118-128	FK506 binding protein 4	Mus musculus	146-152
25986565-11	2015	Thus, the targeting of FKBP52 proline-rich loop interactions is the most attractive therapeutic approach to disrupt FKBP52 regulation of receptor activity in steroid hormone receptor-dependent physiology and disease.	Proline	30-37	FK506 binding protein 4	Mus musculus	23-29
25986565-11	2015	Thus, the targeting of FKBP52 proline-rich loop interactions is the most attractive therapeutic approach to disrupt FKBP52 regulation of receptor activity in steroid hormone receptor-dependent physiology and disease.	Proline	30-37	FK506 binding protein 4	Mus musculus	116-122
20605780-7	2010	Supplementation of gestating females with excess testosterone partially rescued the hypospadic phenotype in Fkbp52 mutant males, showing that loss of Fkbp52 desensitizes AR to hormonal activation.	Testosterone	49-61	FK506 binding protein 4	Mus musculus	108-114
22091865-1	2012	BACKGROUND AND PURPOSE The immunosuppressive macrolide FK506 (tacrolimus) shows neuroregenerative action by a mechanism that appears to involve the Hsp90-binding immunophilin FKBP52.	Macrolides	45-54	FK506 binding protein 4	Mus musculus	175-181
22091865-1	2012	BACKGROUND AND PURPOSE The immunosuppressive macrolide FK506 (tacrolimus) shows neuroregenerative action by a mechanism that appears to involve the Hsp90-binding immunophilin FKBP52.	Tacrolimus	55-60	FK506 binding protein 4	Mus musculus	175-181
22091865-1	2012	BACKGROUND AND PURPOSE The immunosuppressive macrolide FK506 (tacrolimus) shows neuroregenerative action by a mechanism that appears to involve the Hsp90-binding immunophilin FKBP52.	Tacrolimus	62-72	FK506 binding protein 4	Mus musculus	175-181
22091865-6	2012	KEY RESULTS In undifferentiated cells, FKBP52, Hsp90 and p23 are located in the cell nucleus, forming an annular structure that disassembles when the differentiation process is triggered by FK506.	Tacrolimus	190-195	FK506 binding protein 4	Mus musculus	39-45
22416080-7	2012	Lgals1 expression was much lower in d 4 Fkbp52(-/-) uteri compared with WT uteri, and this reduction was reversed by P(4) supplementation.	propiverine	117-121	FK506 binding protein 4	Mus musculus	40-46
25505617-7	2014	Using 52KO and 51KO MEF cells, FK506 potentiated GR activity in 51KO cells but could not do so in 52KO cells, suggesting FKBP52 as the major target of FK506 action.	Tacrolimus	31-36	FK506 binding protein 4	Mus musculus	121-127
25505617-7	2014	Using 52KO and 51KO MEF cells, FK506 potentiated GR activity in 51KO cells but could not do so in 52KO cells, suggesting FKBP52 as the major target of FK506 action.	Tacrolimus	151-156	FK506 binding protein 4	Mus musculus	121-127
25505617-10	2014	Thus, timcodar appears to have a dual specificity for FKBP51 and FKBP52.	timcodar	6-14	FK506 binding protein 4	Mus musculus	65-71
22641006-8	2012	At the same time, Fkbp52(+/-) mice also demonstrated signs of stress resilience in other behavioral and neuroendocrine aspects, such as reduced basal corticosterone levels and more active stress-coping behavior in the FST following CSDS.	Corticosterone	150-164	FK506 binding protein 4	Mus musculus	18-24
21511531-5	2011	Recent studies demonstrated that the FKBP52 FK1 domain and the proline-rich loop within this domain are functionally important for FKBP52 regulation of receptor function.	Proline	63-70	FK506 binding protein 4	Mus musculus	131-137
20713718-1	2010	Immunophilin FK506-binding protein 52 (FKBP52) is a cochaperone that binds to the progesterone receptor (PR) to optimize progesterone (P(4))-PR signaling.	cochaperone	52-63	FK506 binding protein 4	Mus musculus	13-37
20713718-1	2010	Immunophilin FK506-binding protein 52 (FKBP52) is a cochaperone that binds to the progesterone receptor (PR) to optimize progesterone (P(4))-PR signaling.	cochaperone	52-63	FK506 binding protein 4	Mus musculus	39-45
20713718-1	2010	Immunophilin FK506-binding protein 52 (FKBP52) is a cochaperone that binds to the progesterone receptor (PR) to optimize progesterone (P(4))-PR signaling.	Progesterone	82-94	FK506 binding protein 4	Mus musculus	13-37
20713718-1	2010	Immunophilin FK506-binding protein 52 (FKBP52) is a cochaperone that binds to the progesterone receptor (PR) to optimize progesterone (P(4))-PR signaling.	Progesterone	82-94	FK506 binding protein 4	Mus musculus	39-45
20713718-2	2010	We recently showed that Fkbp52-deficient (Fkbp52(-/-)) mice have reduced uterine PR responsiveness and implantation failure which is rescued by excess P(4) supplementation in a genetic background-dependent manner.	propiverine	151-155	FK506 binding protein 4	Mus musculus	24-30
20713718-5	2010	We also found that Fkbp52(-/-) mice with reduced uterine PRDX6 levels are susceptible to paraquat-induced oxidative stress (OS), leading to implantation failure even with P(4) supplementation.	Paraquat	89-97	FK506 binding protein 4	Mus musculus	19-25
20713718-7	2010	Moreover, treatment with antioxidants alpha-tocopherol and N-acetylcysteine (NAC) attenuated paraquat-induced implantation failure in P(4)-treated Fkbp52(-/-) mice.	alpha-Tocopherol	38-54	FK506 binding protein 4	Mus musculus	147-153
20713718-7	2010	Moreover, treatment with antioxidants alpha-tocopherol and N-acetylcysteine (NAC) attenuated paraquat-induced implantation failure in P(4)-treated Fkbp52(-/-) mice.	Acetylcysteine	59-75	FK506 binding protein 4	Mus musculus	147-153
20713718-7	2010	Moreover, treatment with antioxidants alpha-tocopherol and N-acetylcysteine (NAC) attenuated paraquat-induced implantation failure in P(4)-treated Fkbp52(-/-) mice.	Acetylcysteine	77-80	FK506 binding protein 4	Mus musculus	147-153
20713718-7	2010	Moreover, treatment with antioxidants alpha-tocopherol and N-acetylcysteine (NAC) attenuated paraquat-induced implantation failure in P(4)-treated Fkbp52(-/-) mice.	Paraquat	93-101	FK506 binding protein 4	Mus musculus	147-153
20713718-8	2010	Functional analyses using mouse embryonic fibroblasts show that Fkbp52 deficiency associated with reduced PRDX6 levels promotes H(2)O(2)-induced cell death, which is reversed by the addition of NAC or by forced expression of PRDX6, suggesting that Fkbp52 deficiency diminishes the threshold against OS by reducing PRDX6 levels.	Hydrogen Peroxide	128-136	FK506 binding protein 4	Mus musculus	64-70
20713718-8	2010	Functional analyses using mouse embryonic fibroblasts show that Fkbp52 deficiency associated with reduced PRDX6 levels promotes H(2)O(2)-induced cell death, which is reversed by the addition of NAC or by forced expression of PRDX6, suggesting that Fkbp52 deficiency diminishes the threshold against OS by reducing PRDX6 levels.	Hydrogen Peroxide	128-136	FK506 binding protein 4	Mus musculus	248-254
20713718-8	2010	Functional analyses using mouse embryonic fibroblasts show that Fkbp52 deficiency associated with reduced PRDX6 levels promotes H(2)O(2)-induced cell death, which is reversed by the addition of NAC or by forced expression of PRDX6, suggesting that Fkbp52 deficiency diminishes the threshold against OS by reducing PRDX6 levels.	Acetylcysteine	194-197	FK506 binding protein 4	Mus musculus	64-70
20605780-7	2010	Supplementation of gestating females with excess testosterone partially rescued the hypospadic phenotype in Fkbp52 mutant males, showing that loss of Fkbp52 desensitizes AR to hormonal activation.	Testosterone	49-61	FK506 binding protein 4	Mus musculus	150-156
17307907-1	2007	FKBP52 is a member of the FK506-binding family of immunophilins and serves as a co-chaperone for steroid hormone nuclear receptors to govern appropriate hormone action in target tissues.	Tacrolimus	26-31	FK506 binding protein 4	Mus musculus	0-6
20427484-8	2010	Consistent with this hypothesis, reduced expression of gluconeogenic genes and CEACAM1 was observed in dexamethasone-treated FKBP52-deficient mouse embryonic fibroblast cells.	Dexamethasone	103-116	FK506 binding protein 4	Mus musculus	125-131
20427484-9	2010	We propose a model in which FKBP52 loss reduces GR control of gluconeogenesis, predisposing the liver to steatosis under HF-diet conditions attributable to a shunting of metabolism from glucose production to lipogenesis.	Glucose	186-193	FK506 binding protein 4	Mus musculus	28-34
18496572-4	2008	Our previous studies have documented that dephosphorylation of FKBP52 at tyrosine residues by the cellular T-cell protein tyrosine phosphatase (TC-PTP), and at serine/threonine residues by protein phosphatase 5 (PP5) enhances viral second-strand DNA synthesis and consequently, the transgene expression.	Tyrosine	73-81	FK506 binding protein 4	Mus musculus	63-69
18496572-4	2008	Our previous studies have documented that dephosphorylation of FKBP52 at tyrosine residues by the cellular T-cell protein tyrosine phosphatase (TC-PTP), and at serine/threonine residues by protein phosphatase 5 (PP5) enhances viral second-strand DNA synthesis and consequently, the transgene expression.	Serine	160-166	FK506 binding protein 4	Mus musculus	63-69
18496572-4	2008	Our previous studies have documented that dephosphorylation of FKBP52 at tyrosine residues by the cellular T-cell protein tyrosine phosphatase (TC-PTP), and at serine/threonine residues by protein phosphatase 5 (PP5) enhances viral second-strand DNA synthesis and consequently, the transgene expression.	Threonine	167-176	FK506 binding protein 4	Mus musculus	63-69
17717070-3	2007	These results have been confirmed in fkbp4 gene knockout mice in which males are partially androgen insensitive and females display characteristics of progesterone insensitivity.	Progesterone	151-163	FK506 binding protein 4	Mus musculus	37-42
16873445-5	2006	FKBP52 (-/-) uteri showed a normal growth response to estradiol, and unaltered expression of genes controlled by ER and PR-B.	Estradiol	54-63	FK506 binding protein 4	Mus musculus	0-6
12427021-3	2002	The functional role for the PPIase domain in receptor movement was demonstrated by showing that expression of the PPIase domain fragment of FKBP52 in 3T3 cells inhibits dexamethasone-dependent nuclear translocation of a green fluorescent protein-glucocorticoid receptor chimera.	Dexamethasone	169-182	FK506 binding protein 4	Mus musculus	140-146
15528267-11	2005	Furthermore, FKBP52 shows differential cell-specific expression in the uterus in response to progesterone and/or estrogen consistent with its expression patterns during the periimplantation period.	Progesterone	93-105	FK506 binding protein 4	Mus musculus	13-19
34072036-9	2021	Dexamethasone tended to decrease Fkbp4 protein levels, while it increased Fkpb5 mRNA and its protein levels.	Dexamethasone	0-13	FK506 binding protein 4	Mus musculus	33-38
11278753-6	2001	Here we show that cotransfection of 3T3 cells with the FKBP52 PPIase domain and a green fluorescent protein (GFP) glucocorticoid receptor (GR) chimera inhibits dexamethasone-dependent movement of the GFP-GR from the cytoplasm to the nucleus.	Dexamethasone	160-173	FK506 binding protein 4	Mus musculus	55-61
11278753-8	2001	Inhibition of movement by the FKBP52 PPIase domain is abrogated in cells treated with colcemid to eliminate microtubules prior to steroid addition.	Steroids	130-137	FK506 binding protein 4	Mus musculus	30-36
7544801-4	1995	Here we report the localization of FKBP59-HBI in various non lymphoid cells (mouse fibroblasts (L-929), monkey kidney cells (Cos-7), Madin-Darby canine kidney epithelial cells (MDCK), and mouse neuronal cells (GT1)).	carbonyl sulfide	125-128	FK506 binding protein 4	Mus musculus	35-41
34238731-1	2021	OBJECTIVE: To investigate the role of FKBP4 protein in cisplatin-induced premature ovarian insufficiency (POI).	Cisplatin	55-64	FK506 binding protein 4	Mus musculus	38-43
34238731-2	2021	OBJECTIVE: We performed ITRAQ assay of the ovarian tissues from 4 mice with cisplatin-induced POI and 4 control mice, and identified FKBP4 as a significantly down-regulated protein in the oocytes and granulosa cells following cisplatin treatment.	Cisplatin	76-85	FK506 binding protein 4	Mus musculus	133-138
34238731-2	2021	OBJECTIVE: We performed ITRAQ assay of the ovarian tissues from 4 mice with cisplatin-induced POI and 4 control mice, and identified FKBP4 as a significantly down-regulated protein in the oocytes and granulosa cells following cisplatin treatment.	Cisplatin	226-235	FK506 binding protein 4	Mus musculus	133-138
34238731-8	2021	OBJECTIVE: Ovarian FKBP4 expression was significantly decreased in mice with cisplatin-induced POI.	Cisplatin	77-86	FK506 binding protein 4	Mus musculus	19-24
34238731-9	2021	Analysis using TargetScan software indicated that FKBP4 was the potential target of miR-483-5p, which was highly expressed in the ovaries and serum of POI mice and in the serum of patients with POI.	mir-483-5p	84-94	FK506 binding protein 4	Mus musculus	50-55
34238731-13	2021	OBJECTIVE: miR-483-5p/FKBP4 is a new and important pathway in cisplatin-induced POI, in which cisplatin increases ovarian miR- 483-5p expression to result in targeted downregulation of FKBP4.	Cisplatin	62-71	FK506 binding protein 4	Mus musculus	22-27
34238731-13	2021	OBJECTIVE: miR-483-5p/FKBP4 is a new and important pathway in cisplatin-induced POI, in which cisplatin increases ovarian miR- 483-5p expression to result in targeted downregulation of FKBP4.	Cisplatin	62-71	FK506 binding protein 4	Mus musculus	185-190
34238731-13	2021	OBJECTIVE: miR-483-5p/FKBP4 is a new and important pathway in cisplatin-induced POI, in which cisplatin increases ovarian miR- 483-5p expression to result in targeted downregulation of FKBP4.	Cisplatin	94-103	FK506 binding protein 4	Mus musculus	22-27
34238731-13	2021	OBJECTIVE: miR-483-5p/FKBP4 is a new and important pathway in cisplatin-induced POI, in which cisplatin increases ovarian miR- 483-5p expression to result in targeted downregulation of FKBP4.	Cisplatin	94-103	FK506 binding protein 4	Mus musculus	185-190
11005382-13	2000	Treatment of Hepa-1 cells with the hsp90-binding benzoquinone ansamycin, geldanamycin, and the macrocyclic antifungal compound radicicol resulted in AhR but not XAP2 or FKBP52 turnover.	monorden	127-136	FK506 binding protein 4	Mus musculus	169-175
9036943-3	1997	We previously reported the appearance of a protein doublet at 120 and 130 kDa that preferentially associates with p59(fyn) and undergoes tyrosine phosphorylation upon receptor ligation.	Tyrosine	137-145	FK506 binding protein 4	Mus musculus	114-117
33182400-9	2020	Moreover, the Leu319Pro amino acid substitution occurred in a highly conserved position of the FKBP4 region, responsible for interaction with other proteins that are crucial for the AR functional heterocomplex formation and therefore the substitution is predicted to cause the disease.	leu319pro	14-23	FK506 binding protein 4	Mus musculus	95-100
34072036-4	2021	Glucocorticoid signaling is mediated via glucocorticoid receptors, 11beta-hydroxysteroid dehydrogenases, and the FK506-binding immunophilins, Fkbp4 and Fkbp5.	Tacrolimus	113-118	FK506 binding protein 4	Mus musculus	142-147
34072036-6	2021	Here, we explored the regulation of Fkbp4 and Fkbp5 genes and their proteins with dexamethasone, a major synthetic glucocorticoid drug, in murine AtT-20 corticotroph cells.	Dexamethasone	82-95	FK506 binding protein 4	Mus musculus	36-41
32828804-0	2020	Proof that the high molecular weight immunophilin FKBP52 mediates the in vivo neuroregenerative effect of the macrolide FK506.	Macrolides	110-119	FK506 binding protein 4	Mus musculus	37-56
32828804-0	2020	Proof that the high molecular weight immunophilin FKBP52 mediates the in vivo neuroregenerative effect of the macrolide FK506.	Tacrolimus	120-125	FK506 binding protein 4	Mus musculus	37-56
32828804-6	2020	The experimental evidence demonstrates that the neurotrophic actions of FK506 are the consequence of its binding to FKBP52, whereas FK506 interaction with the close-related partner immunophilin FKBP51 antagonises the function of FKBP52.	Tacrolimus	72-77	FK506 binding protein 4	Mus musculus	116-122
32828804-6	2020	The experimental evidence demonstrates that the neurotrophic actions of FK506 are the consequence of its binding to FKBP52, whereas FK506 interaction with the close-related partner immunophilin FKBP51 antagonises the function of FKBP52.	Tacrolimus	132-137	FK506 binding protein 4	Mus musculus	229-235
2557544-13	1989	We conclude that p59(fyn) phosphorylation is increased in membranes from lpr/lpr CD4(-) CD8(-) T cells and that the increase is correlated with constitutive tyrosine phosphorylation and perhaps with the expansion of this unusual T-cell population.	Tyrosine	157-165	FK506 binding protein 4	Mus musculus	17-20
28689771-0	2018	Immunosuppression with tacrolimus improved implantation and rescued expression of uterine progesterone receptor and its co-regulators FKBP52 and PIASy at nidation in the obese and diabetic mice: Comparative studies with metformin.	Tacrolimus	23-33	FK506 binding protein 4	Mus musculus	134-140
28689771-8	2018	Therapeutic interventions with tacrolimus or metformin normalized the expression of decidual IFNgamma, PGR and FKBP52, increased co-localization of protein inhibitor of activated STATy (PIASy) to PGR and resulted in the upregulation of uterine IL11and LIF.	Tacrolimus	31-41	FK506 binding protein 4	Mus musculus	111-117
28689771-8	2018	Therapeutic interventions with tacrolimus or metformin normalized the expression of decidual IFNgamma, PGR and FKBP52, increased co-localization of protein inhibitor of activated STATy (PIASy) to PGR and resulted in the upregulation of uterine IL11and LIF.	Metformin	45-54	FK506 binding protein 4	Mus musculus	111-117